Advancements in dementia research, diagnostics, and care in Latin America: Highlights from the 2023 Alzheimer's Association International conference satellite symposium in Mexico City.

Results numerically favored crenezumab across primary and secondary outcomes, but they did not reach statistical significance. 139 , 140 While the API ADAD Colombia trial results were negative, it led to the discovery of protective genetic variants 35 , 36 , 94 and additional pathogenic PSEN1 mutations in Colombia, 41 as described in more detail in Section 4 of this manuscript. 10.

also in 111,027 other papers